
[Federal Register Volume 77, Number 40 (Wednesday, February 29, 2012)]
[Notices]
[Pages 12309-12310]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-4783]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-P-0558]


Determination That PHENURONE (Phenacemide) Tablet, 500 
Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or 
Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined that 
PHENURONE (phenacemide) Tablet, 500 milligrams (mg), was not withdrawn 
from sale for reasons of safety or effectiveness. This determination 
will allow FDA to approve abbreviated new drug applications (ANDAs) for 
phenacemide tablet, 500 mg, if all other legal and regulatory 
requirements are met.

FOR FURTHER INFORMATION CONTACT: Howard P. Muller, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6234, Silver Spring, MD 20993-0002, 301-
796-3602.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price 
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) 
(the 1984 amendments), which authorized the approval of duplicate 
versions of drug products approved under an ANDA procedure. ANDA 
applicants must, with certain exceptions, show that the drug for which 
they are seeking approval contains the same active ingredient in the 
same strength and dosage form as the ``listed drug,'' which is a 
version of the drug that was previously approved. ANDA applicants do 
not have to repeat the extensive clinical testing otherwise necessary 
to gain approval of a new drug application (NDA). The only clinical 
data required in an ANDA are data to show that the drug that is the 
subject of the ANDA is bioequivalent to the listed drug.
    The 1984 amendments include what is now section 505(j)(7) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which 
requires FDA to publish a list of all approved drugs. FDA publishes 
this list as part of the ``Approved Drug Products With Therapeutic 
Equivalence Evaluations,'' which is known generally as the ``Orange 
Book.'' Under FDA regulations, drugs are removed from the list if the 
Agency withdraws or suspends approval of the drug's NDA or ANDA for 
reasons of safety or effectiveness or if FDA determines that the listed 
drug was withdrawn from sale for reasons of safety or effectiveness (21 
CFR 314.162).
    A person may petition the Agency to determine, or the Agency may 
determine on its own initiative, whether a listed drug was withdrawn 
from sale for reasons of safety or effectiveness. This determination 
may be made at any time after the drug has been withdrawn from sale, 
but must be made prior to approving an ANDA that refers to the listed 
drug (Sec.  314.161 (21 CFR 314.161)). FDA may not approve an ANDA that 
does not refer to a listed drug.
    PHENURONE (phenacemide) Tablet, 500 mg, is the subject of NDA 
007707, held by Abbott Laboratories, and initially approved on June 28, 
1951. PHENURONE is an oral anticonvulsant indicated for the treatment 
of epilepsy.
    In a letter dated May 14, 2003, Abbott Laboratories requested 
withdrawal of NDA 007707 for PHENURONE (phenacemide) Tablet. In the 
Federal Register of May 5, 2004 (69 FR 25124), FDA announced that it 
was withdrawing approval of NDA 007707, effective June 4, 2004.
    Schiff & Company submitted a citizen petition dated October 16, 
2008 (Docket No. FDA-2008-P-0558), under 21 CFR 10.30, requesting that 
the Agency determine whether PHENURONE (phenacemide) Tablet, 500 mg, 
was withdrawn from sale for reasons of safety or effectiveness.
    After considering the citizen petition and reviewing Agency 
records, FDA has determined under Sec.  314.161 that PHENURONE 
(phenacemide) Tablet, 500 mg, was not withdrawn for reasons of safety 
or effectiveness. The petitioner has identified no data or other 
information suggesting that PHENURONE (phenacemide) tablet, 500 mg, was 
withdrawn for reasons of safety or effectiveness. We have carefully 
reviewed our files for records concerning the withdrawal of

[[Page 12310]]

PHENURONE (phenacemide) Tablet, 500 mg, from sale. We have also 
independently evaluated relevant literature and data for possible 
postmarketing adverse events. We have found no information that would 
indicate that this product was withdrawn from sale for reasons of 
safety or effectiveness.
    Accordingly, the Agency will continue to list PHENURONE 
(phenacemide) Tablet, 500 mg, in the ``Discontinued Drug Product List'' 
section of the Orange Book. The ``Discontinued Drug Product List'' 
delineates, among other items, drug products that have been 
discontinued from marketing for reasons other than safety or 
effectiveness. ANDAs that refer to PHENURONE (phenacemide) Tablet, 500 
mg, may be approved by the Agency as long as they meet all other legal 
and regulatory requirements for the approval of ANDAs. If FDA 
determines that labeling for this drug product should be revised to 
meet current standards, the Agency will advise ANDA applicants to 
submit such labeling.

    Dated: February 23, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-4783 Filed 2-28-12; 8:45 am]
BILLING CODE 4160-01-P


